Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...

"Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," said senior author of the study Dr ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial ... Intravenous; mCRPC: Metastatic castration-resistant prostate cancer; P: Placebo; PSA: Prostate ...

"Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," said senior author of the study Dr ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

A new test for prostate cancer developed by Irish and Swedish researchers better predicts the risks of the aggressive disease and means some men could avoid unnecessary treatment. Prostate cancer ...

This follows the initial licence for treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in 2020. Following entry into a commercial agreement with Bayer ...

The study, published in JAMA Network Open, found that nearly half of high-risk prostate cancer patients previously classified as nonmetastatic by conventional imaging actually have metastatic disease ...